Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niels Jongs

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|December 12, 2024
Improving Patient Selection in Clinical Trials: Should We Start Using the Pretrial eGFR Decline as Risk Enrichment Criterion?Niels Jongs, Hiddo J L Heerspink
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 23, 2025
What are the right endpoints to assess the effectiveness of new treatments for IgAN?Niels Jongs, Hiddo J L Heerspink
Kidney International|August 20, 2023
The authors replyHiddo J L Heerspink, Niels Jongs, Brendon L Neuen
Diabetes Care|January 19, 2024
Response to Comment on Curovic et al. Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial. Diabetes Care 2023;46:593-601Viktor Rotbain Curovic, Frederik Persson, Niels Jongs, et al.
JAMA Network Open|March 24, 2025
Albuminuria Responses to Dapagliflozin in Patients With Type 2 Diabetes: A Crossover TrialJelle M Beernink, Niels Jongs, Cees J A Doelman, et al.
Kidney International|March 26, 2025
Contribution of the glomerular filtration rate slope to the kidney hierarchical composite endpointDustin J Little, Niels Jongs, Meike Brinker, et al.
JAMA Network Open|April 27, 2023
Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical TrialPriya Vart, Niels Jongs, David C Wheeler, et al.
Kidney International|July 5, 2024
Clinical trial designs to assess treatment effects on glomerular filtration rate declineHiddo J L Heerspink, Dustin J Little, Lars Frison, et al.
Journal of the American Society of Nephrology : JASN|June 17, 2025
Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End PointNiels Jongs, Samvel B Gasparyan, Lars Frison, et al.
Diabetes, Obesity & Metabolism|May 11, 2023
Effects of albuminuria-lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trialsTaha Sen, Viktor Rotbain Curovic, Niels Jongs, et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Clinical Journal of the American Society of Nephrology : CJASN|December 12, 2024
Improving Patient Selection in Clinical Trials: Should We Start Using the Pretrial eGFR Decline as Risk Enrichment Criterion?Niels Jongs, Hiddo J L Heerspink
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 23, 2025
What are the right endpoints to assess the effectiveness of new treatments for IgAN?Niels Jongs, Hiddo J L Heerspink
Kidney International|August 20, 2023
The authors replyHiddo J L Heerspink, Niels Jongs, Brendon L Neuen
Diabetes Care|January 19, 2024
Response to Comment on Curovic et al. Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial. Diabetes Care 2023;46:593-601Viktor Rotbain Curovic, Frederik Persson, Niels Jongs, et al.
JAMA Network Open|March 24, 2025
Albuminuria Responses to Dapagliflozin in Patients With Type 2 Diabetes: A Crossover TrialJelle M Beernink, Niels Jongs, Cees J A Doelman, et al.
Kidney International|March 26, 2025
Contribution of the glomerular filtration rate slope to the kidney hierarchical composite endpointDustin J Little, Niels Jongs, Meike Brinker, et al.
JAMA Network Open|April 27, 2023
Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical TrialPriya Vart, Niels Jongs, David C Wheeler, et al.
Kidney International|July 5, 2024
Clinical trial designs to assess treatment effects on glomerular filtration rate declineHiddo J L Heerspink, Dustin J Little, Lars Frison, et al.
Journal of the American Society of Nephrology : JASN|June 17, 2025
Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End PointNiels Jongs, Samvel B Gasparyan, Lars Frison, et al.
Diabetes, Obesity & Metabolism|May 11, 2023
Effects of albuminuria-lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trialsTaha Sen, Viktor Rotbain Curovic, Niels Jongs, et al.
Pageof 8